1. Combined inhibition of SHP2 and ERK enhances anti-tumour effects in preclinical models. (October 2020) Authors: Smyth, T.; Brothwood, J.; Fazal, L.; Hearn, K.; Hindley, C.; Johnson, C.; Jones, M.; Kandola, N.; Lyons, J.; Martins, V.; Miyadera, K.; Muench, S.; Munck, J.; Nakatsuru, Y.; Ochiiwa, H.; Saini, H.; Shah, A.; Wagner, S.; Wilsher, N.; Wallis, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models. (October 2020) Authors: Munck, J.; Berdini, V.; Courtin, A.; East, C.; Heightman, T.; Hindley, C.; Kucia-Tran, J.; Lyons, J.; Martins, V.; Muench, S.; Murray, C.; Norton, D.; O'Reilly, M.; Reader, M.; Rees, D.; Rich, S.; Thompson, N.; Wilsher, N.; Woolford, A.; Wallis, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The non-peptidomimetic cIAP1/2 and XIAP antagonist ASTX660 promotes an anti-tumour immune response in T-cell lymphoma. (October 2020) Authors: Ferrari, N.; Ward, G.; Gewinner, C.; Jueliger, S.; Smyth, T.; Munck, J.; Davis, M.; Ferraldeschi, R.; Lyons, J.; Sims, M. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗